What it's for (Indications)
- Rosuvastatin calcium + ezetimibe is indicated as an adjunctive therapy to diet to reduce elevated total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (ApoB), and triglycerides (TG), and to increase high-density lipoprotein cholesterol (HDL-C) in adult patients with primary hyperlipidemia (heterozygous familial and non-familial).
- This combination therapy is specifically beneficial when a statin alone is not sufficient to achieve target LDL-C levels, or when patients require a higher intensity statin therapy and additional LDL-C reduction is needed.
- It is also indicated for the reduction of the risk of major cardiovascular events in patients with coronary heart disease (CHD) and a history of acute coronary syndrome (ACS).
- Furthermore, it may be used in patients with homozygous familial hypercholesterolemia (HoFH) as an adjunct to other lipid-lowering treatments (e.
- g.
- , LDL apheresis) or if such treatments are unavailable, demonstrating its utility in severe forms of dyslipidemia.
- Its use is predicated on the clinical need for dual lipid modification to achieve therapeutic goals in appropriate patient populations.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage of rosuvastatin calcium + ezetimibe must be individualized based on the patient's baseline lipid levels, established cardiovascular risk, and response to previous lipid-lowering therapy. The fixed-dose combination is available in various strengths, such as rosuvastatin 5 mg/ezetimibe 10 mg, 10 mg/10 mg, 20 mg/10 mg, and 40 mg/10 mg. It is administered orally once daily, with or without food. For most patients, an initial dose of 10 mg rosuvastatin combined with 10 mg ezetimibe is common, with titration based on lipid goals. The maximum recommended daily dose for the rosuvastatin component is 40 mg. Renal impairment necessitates careful consideration; in patients with severe renal impairment (creatinine clearance < 30 mL/min), the 40 mg rosuvastatin dose is contraindicated, and lower doses should be used cautiously. Hepatic impairment, particularly active liver disease, is a contraindication. When co-administered with cyclosporine, the rosuvastatin component should not exceed 5 mg once daily. Similarly, with gemfibrozil, the rosuvastatin dose should not exceed 10 mg once daily due to increased exposure risks and heightened risk of myopathy. Dosing should always consider potential drug interactions and patient-specific factors. |
Safety & Warnings
Common Side Effects
- Patients receiving rosuvastatin calcium + ezetimibe may experience a range of side effects, which are generally mild and transient.
- Common adverse reactions include headache, myalgia (muscle pain), arthralgia (joint pain), asthenia (weakness), constipation, nausea, abdominal pain, diarrhea, nasopharyngitis, and influenza-like illness.
- Clinically significant, though less common, side effects include elevations in liver transaminases (ALT/AST), which may necessitate discontinuation if persistent and significantly elevated.
- More serious potential adverse effects, which warrant immediate medical attention, encompass myopathy and rhabdomyolysis.
- Myopathy is characterized by muscle pain, tenderness, or weakness accompanied by creatine kinase (CK) levels exceeding 10 times the upper limit of normal (ULN); rhabdomyolysis is a severe form that can lead to acute renal failure.
- Other rare but serious adverse events reported with statins include immune-mediated necrotizing myopathy (IMNM), new-onset diabetes mellitus, peripheral neuropathy, and hypersensitivity reactions such as rash, pruritus, and angioedema.
- Patients should be counseled to report any unusual muscle symptoms, dark urine, or signs of allergic reaction promptly to their healthcare provider to allow for timely intervention and prevent severe complications.
Serious Warnings
- Black Box Warning: A formal FDA Black Box Warning, indicating the most severe potential risks, has not been established for the fixed-dose combination of rosuvastatin calcium and ezetimibe. However, prescribers and patients should be acutely aware of significant safety concerns, predominantly related to the rosuvastatin component, which necessitate careful monitoring and patient education. **Serious Warnings** **Skeletal Muscle Effects:** The most critical serious warning pertains to the risk of myopathy, characterized by muscle pain, tenderness, or weakness, and potentially progressing to rhabdomyolysis, a severe muscle condition that can lead to acute renal failure and, rarely, death. The risk is dose-related for rosuvastatin and is increased by predisposing factors such as advanced age (>65 years), renal impairment, uncontrolled hypothyroidism, and concomitant use of certain medications (e.g., cyclosporine, gemfibrozil, other fibrates, high-dose niacin, specific protease inhibitors). Patients must be explicitly instructed to report any unexplained muscle pain, tenderness, or weakness, especially if accompanied by malaise or fever, immediately to their healthcare provider. Serum creatine kinase (CK) levels should be measured in these situations, and the drug should be discontinued if CK levels are significantly elevated (>10 times the upper limit of normal) or if myopathy is diagnosed or strongly suspected. **Liver Enzyme Abnormalities:** Persistent elevations in serum transaminases (ALT or AST > 3 times the upper limit of normal) have been reported with statin therapy. While generally dose-related and reversible upon discontinuation, these elevations can indicate serious liver injury. Liver function tests should be performed prior to initiating treatment and as clinically indicated thereafter. The drug should be used with caution in patients who consume substantial quantities of alcohol and is contraindicated in patients with active liver disease or unexplained persistent transaminase elevations. If transaminase levels remain elevated and progressive, or if accompanied by signs and symptoms of liver injury (e.g., jaundice, dark urine), the drug should be discontinued. These serious warnings underscore the importance of vigilant monitoring and patient counseling during therapy.
- Several critical warnings must be considered when prescribing or using rosuvastatin calcium + ezetimibe.
- The primary concern revolves around **Skeletal Muscle Effects**, specifically myopathy and rhabdomyolysis, which can lead to renal failure.
- Patients should be instructed to immediately report any unexplained muscle pain, tenderness, or weakness, especially if accompanied by malaise or fever.
- Creatine kinase levels should be measured in such instances, and therapy should be discontinued if CK levels are significantly elevated or if myopathy is diagnosed.
- The risk of myopathy is increased with higher doses of rosuvastatin, advanced age, renal impairment, uncontrolled hypothyroidism, and concomitant use with certain drugs like cyclosporine, gemfibrozil, other fibrates, and high-dose niacin.
- **Liver Enzyme Abnormalities** are another significant warning; persistent elevations of serum transaminases (ALT or AST > 3 times ULN) have occurred.
- Liver function tests should be performed prior to initiation and as clinically indicated, with discontinuation considered if elevations persist.
- Rosuvastatin + ezetimibe is contraindicated in patients with active liver disease.
- **New-Onset Diabetes Mellitus** has been reported with statin therapy, including rosuvastatin, indicating a potential slight increase in HbA1c and fasting blood glucose levels.
- Prescribers should weigh this risk against the substantial cardiovascular benefits.
- Dosage adjustments may be necessary in patients with **Severe Renal Impairment** (CrCl < 30 mL/min), and the 40 mg rosuvastatin dose is contraindicated in this population.
- **Endocrine function** changes, including increases in HbA1c and fasting blood glucose, have also been observed.
- Careful consideration of **concomitant medications** is essential; for example, the risk of myopathy is significantly increased with co-administration of cyclosporine (rosuvastatin dose limit 5 mg), gemfibrozil (rosuvastatin dose limit 10 mg), and certain protease inhibitors.
- Patients on oral anticoagulants should have their International Normalized Ratio (INR) closely monitored due to potential interactions.
- Furthermore, cases of myopathy/rhabdomyolysis have been reported with concurrent use of colchicine and statins, necessitating caution.
How it Works (Mechanism of Action)
Rosuvastatin calcium + ezetimibe provides a synergistic lipid-lowering effect through two distinct yet complementary mechanisms. Rosuvastatin, belonging to the class of HMG-CoA reductase inhibitors (statins), acts primarily in the liver. It potently and selectively competes with HMG-CoA for the active site of the enzyme HMG-CoA reductase, which is the rate-limiting enzyme in the hepatic biosynthesis of cholesterol. By inhibiting this enzyme, rosuvastatin significantly decreases intracellular cholesterol synthesis. This reduction in hepatic cholesterol content triggers an upregulation of hepatic low-density lipoprotein (LDL) receptors on the surface of liver cells. These increased LDL receptors enhance the clearance of circulating LDL-cholesterol from the bloodstream, thereby lowering plasma LDL-C levels. Rosuvastatin also decreases very low-density lipoprotein (VLDL) production and triglyceride (TG) levels, while modestly increasing high-density lipoprotein cholesterol (HDL-C). Ezetimibe, on the other hand, acts by inhibiting the absorption of cholesterol at the brush border of the small intestine. It selectively targets the Niemann-Pick C1-Like 1 (NPC1L1) protein, a critical mediator of intestinal cholesterol and phytosterol absorption. By blocking NPC1L1, ezetimibe reduces the uptake of both dietary and biliary cholesterol into enterocytes. This reduction in intestinal cholesterol absorption decreases the delivery of cholesterol to the liver, leading to a compensatory upregulation of hepatic LDL receptors, similar to statins, further enhancing LDL-C clearance from the blood. The combination of rosuvastatin and ezetimibe offers a dual inhibition pathway: rosuvastatin reduces endogenous cholesterol synthesis, and ezetimibe reduces exogenous cholesterol absorption. This comprehensive approach results in a more pronounced reduction in LDL-C than achieved with either agent alone, addressing both the endogenous production and exogenous absorption components of cholesterol homeostasis.